Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Database
Language
Publication year range
1.
Phys Rev Lett ; 130(18): 187102, 2023 May 05.
Article in English | MEDLINE | ID: mdl-37204903

ABSTRACT

Interfaces of phase-separated systems roughen in time due to capillary waves. Because of fluxes in the bulk, their dynamics is nonlocal in real space and is not described by the Edwards-Wilkinson or Kardar-Parisi-Zhang (KPZ) equations, nor their conserved counterparts. We show that, in the absence of detailed balance, the phase-separated interface is described by a new universality class that we term |q|KPZ. We compute the associated scaling exponents via one-loop renormalization group and corroborate the results by numerical integration of the |q|KPZ equation. Deriving the effective interface dynamics from a minimal field theory of active phase separation, we finally argue that the |q|KPZ universality class generically describes liquid-vapor interfaces in two- and three-dimensional active systems.

2.
Phys Rev Lett ; 128(21): 219901, 2022 May 27.
Article in English | MEDLINE | ID: mdl-35687475

ABSTRACT

This corrects the article DOI: 10.1103/PhysRevLett.127.068001.

3.
Phys Rev Lett ; 127(6): 068001, 2021 Aug 06.
Article in English | MEDLINE | ID: mdl-34420338

ABSTRACT

In passive fluid-fluid phase separation, a single interfacial tension sets both the capillary fluctuations of the interface and the rate of Ostwald ripening. We show that these phenomena are governed by two different tensions in active systems, and compute the capillary tension σ_{cw} which sets the relaxation rate of interfacial fluctuations in accordance with capillary wave theory. We discover that strong enough activity can cause negative σ_{cw}. In this regime, depending on the global composition, the system self-organizes, either into a microphase-separated state in which coalescence is highly inhibited, or into an "active foam" state. Our results are obtained for Active Model B+, a minimal continuum model which, although generic, admits significant analytical progress.

4.
J Travel Med ; 3(4): 214-218, 1996 Dec 01.
Article in English | MEDLINE | ID: mdl-9815459

ABSTRACT

Background: Hepatitis A virus (HAV) circulation in the environment is decreasing in most industrialized Western countries. This decrease has lead to low seroprevalence rates in adults. As a consequence, many nonimmune unprotected travelers from areas of low prevalence are considered at risk of acquiring HAV infection when traveling to high HAV endemic areas in developing countries. The recent HAV inactivated vaccine has proved safe and effective, and its use in different geographic areas should be guided by local age-specific HAV seroprevalence rates. The aim of this paper is to describe the age-specific sero-epidemiology of HAV infection in travelers from a highly industrialized region in Northern Italy (Lombardy). Methods: Seven hundred and forty-four consecutive travelers aged from 20 to 59 years, subdivided in 10-year age groups, gave blood samples in the collaborative Health Centers in the Lombardy region and sera were tested for HAV IgG antibodies. A questionnaire was given to travelers that investigated alimentary habits and a history of previous travel. Results: Anti-HAV seroprevalence was 18.0%, 58.0%, 75.8%, and 89.5% in the 20-29, 30-39, 40-49, and 50-59 age groups, respectively. Age was the single most important determinant of anti-HAV seroprevalence. The influence of previous travels, eating shellfish, or ingestion of self-cultivated vegetables was ruled out by multivariate analysis. Conclusions: In the Lombardy region (Northern Italy), age specific anti-HAV seroprevalence rates are much higher than those reported in other Western European countries. The cost-benefit analysis suggested that travelers born after 1960 do not need serologic screening before vaccination. Whenever possible, however, HAV serologic screening is advisable for travelers born before 1960. However, the severity of the disease in older subjects, and the proved safety of HAV vaccination in immune subjects, may advise d'emblée HAV vaccination without prior screening, when serologic investigation is unfeasible because of lack of time or the unavailability of testing facilities.

SELECTION OF CITATIONS
SEARCH DETAIL